罕见RIPK3变异增强坏死性凋亡并促进Still病样自身炎症综合征炎症
研究在一个三代家系中鉴定出RIPK3 p.Q134K杂合变异,该变异为功能获得性,可增强RIPK3激酶活性与自关联,促进MLKL磷酸化及坏死性凋亡;患者PBMC中NF-κB和MAPK通路上调、IL-6和TNF-α表达升高,RIPK3药理抑制可有效抑制炎症。
要点
- RIPK3 p.Q134K为功能获得性变异,增强激酶活性与坏死性凋亡。
- 该变异导致Still病样自身炎症综合征,呈家族性聚集。
- RIPK3药理抑制可抑制NF-κB、MAPK通路及IL-6、TNF-α升高。
核心结论
- RIPK3功能获得性变异可驱动自身炎症,扩展了人类RIPK3相关疾病谱。
研究设计与样本
- 对一个三代家系中3例患者行全外显子测序,并开展功能分析、PBMC转录组测序及体外细胞因子检测。
主要发现
- 所有患者均携带杂合RIPK3 p.Q134K变异,该变异增强RIPK3激酶活性与自关联,促进MLKL磷酸化及坏死性凋亡。
- 一例患者PBMC RNA测序显示NF-κB和MAPK信号通路显著上调,IL-6和TNF-α表达升高。
- RIPK3药理抑制可有效抑制上述炎症信号。
临床怎么用
- 对早发或家族性Still病样自身炎症综合征,可考虑RIPK3相关变异筛查及坏死性凋亡通路评估。
局限性
- 研究基于单一家系,功能验证主要来自一例患者PBMC及体外实验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Still disease represents a prototypical polygenic systemic autoinflammatory disease, characterized by recurrent systemic inflammation and dysregulation of innate immunity. Despite extensive clinical characterization, familial clustering Still disease remains unreported. This study investigates a novel variant underlying a distinct Still disease-like autoinflammatory syndrome. METHODS: Whole-exome sequencing was performed in a three-generation family with three affected individuals. Functional analyses were conducted to assess the impact of the receptor-interacting protein kinase 3 (RIPK3) p.Q134K variant on kinase activity, necroptosis, and inflammatory signaling. Transcriptomic profiling of peripheral blood mononuclear cells (PBMCs) and in vitro cytokine assays were used to characterize inflammatory responses. RESULTS: A heterozygous RIPK3 p.Q134K variant was identified in all affected individuals. Functional analyses demonstrated that this variant exhibits gain-of-function activity, characterized by enhanced RIPK3 kinase activity and increased RIPK3 self-association, which in turn promote mixed-lineage kinase domain-like protein phosphorylation and necroptosis. RNA sequencing of PBMCs from one patient revealed marked up-regulation of NF-κB and MAPK signaling pathways and elevated expression of interleukin-6, and tumor necrosis factor-α, which was effectively suppressed by pharmacologic inhibition of RIPK3. CONCLUSION: This study describes a familial Still disease-like autoinflammatory syndrome caused by a gain-of-function RIPK3 variant. Our findings establish aberrant RIPK3 activation as a driver of autoinflammation and expand the spectrum of human RIPK3-associated diseases.
引用
- Chen L, Dai Q, Xiao Y, et al. A Rare RIPK3 Variant Enhances Necroptosis and Promotes Inflammation in a Still Disease-Like Autoinflammatory Syndrome. Arthritis Rheumatol. 2026. PMID: 41854276. doi:10.1002/art.70146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。